Highest-materiality recent filing
Abbott settles NEC litigation for $670M covering Gill case and ~2,000 infants
Agreements resolve $495M Gill verdict plus NEC claims for ~2,000 infants, total ~$670M.
Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60
Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.
Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.
Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58
Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).
Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics
Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
Abbott completes $20B senior notes offering to fund Exact Sciences acquisition
Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.
Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition
Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.
Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80
Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B
Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.
Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance
GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20
GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance
GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).
Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25
Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint
Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance
GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
Abbott Q1 adj. EPS $0.98; raises FY2024 midpoint guidance
Q1 GAAP diluted EPS $0.70; adjusted diluted EPS $0.98; revenue $9.96B (+2.2% reported).
Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70
Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.
Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint
Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).
Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%
Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).
Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%
Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.
Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50
Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.
Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance
Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.
Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+
Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).
Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed
Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.
Abbott recalls Similac infant formula from Sturgis MI plant; reaffirms EPS guidance
Proactive voluntary recall of Similac powder infant formulas from Sturgis, MI facility; primarily US and Canada.
Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70
Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).
Abbott names CEO Robert B. Ford as Chairman; Miles D. White retires
Miles D. White resigns as Executive Chairman and director, effective Dec 10, 2021.
Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance
GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.
On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.
Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.
On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.
On December 9, 2021, Roxanne S. Austin informed the Abbott Laboratories Board of Directors of her decision not to stand for re-election at the end of her current term expiring at the 2022 annual shareholders meeting in April.
On December 10, 2021, Abbott’s Board of Directors appointed Robert B. Ford, Abbott’s President and Chief Executive Officer and a director, to the additional position of Chairman of the Board, effective upon Mr. White’s resignation.
Miles D. White informed the Abbott Laboratories (“Abbott”) Board of Directors that he will step down as Executive Chairman of the Board and as a director, effective December 10, 2021.
On August 30, 2021, Patricia P. Gonzalez was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.
Max materiality 1.00 · Median 0.70 · Most common event earnings